A conformational restriction in the influenza a virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1639-1645

  Huang, Lan ^a,b   Cao, Yang ^c   Zhou, Jianfang ^a   Qin, Kun ^a   Zhu, Wenfei ^a   Zhu, Yun ^a   Yang, Lei ^a   Wang, Dayan ^a   Wei, Hong ^b   Shu, Yuelong ^a  

^a National Institute for Viral Disease Control and Prevention   (China)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; OSELTAMIVIR; SIALIDASE INHIBITOR; VIRUS SIALIDASE;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CELL CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; KIDNEY CELL; MDCK CELL; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; MOLECULAR DYNAMICS; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIROGENESIS; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; DOGS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KIDNEY; MADIN DARBY CANINE KIDNEY CELLS; NEURAMINIDASE; OSELTAMIVIR; PROTEIN CONFORMATION; VIRUS REPLICATION;

EID: 84896878263     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01848-13     Document Type: Article

References (41)

1. Okomo-Adhiambo M, Sheu TG, Gubareva LV. 2013. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir. Viruses 7(Suppl 1):44-49. http://dx.doi.org/10.1111/irv.12051.
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615. http://dx.doi.org/10.1056/ NEJMoa0903810.
3. Meijer A, Jonges M, Abbink F, Ang W, van Beek J, Beersma M, Bloembergen P, Boucher C, Claas E, Donker G, van Gageldonk-Lafeber R, Isken L, de Jong A, Kroes A, Leenders S, van der Lubben M, Mascini E, Niesters B, Oosterheert JJ, Osterhaus A, Riesmeijer R, Riezebos-Brilman A, Schutten M, Sebens F, Stelma F, Swaan C, Timen A, van 't Veen A, van der Vries E, te Wierik M, Koopmans M. 2011. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 92:81-89. http://dx.doi.org/10.1016/j.antiviral.2011.07.004.
4. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A. 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365:2541-2542. http://dx.doi.org/10.1056/NEJMc1111078.
5. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multi-drug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382. http://dx.doi.org/10.1056/NEJMc1003749.
6. Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B. 2011. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob. Agents Chemother. 55:2942-2952. http://dx.doi.org/10.1128/AAC.01699-10.
7. Colman PM, Hoyne PA, Lawrence MC. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980. (Pubitemid 23143664)
8. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17:159-173. http://dx.doi.org/10.3851/IMP2067.
9. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
10. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, Tai L, Roberts N. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54:79-88. http://dx.doi.org/10.1016/S0166-3542(01)00215-7. (Pubitemid 34327686)
11. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111. http://dx.doi.org/10.1016/ S0166-3542(01)00214-5. (Pubitemid 34327688)
12. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80:8787-8795. http://dx.doi.org/10.1128/JVI.00477-06. (Pubitemid 44384887)
13. Ferraris O, Lina B. 2008. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41:13-19. http://dx.doi.org/10.1016/j.jcv.2007.10.020. (Pubitemid 350298978)
14. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. http://dx.doi.org/10.1371/journal.ppat.1000103.
15. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272-1275. http://dx.doi.org/10.1126/science.1187816.
16. Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, Sugawara K, Takashita E, Itagaki T, Katsushima Y, Ujike M, Obuchi M, Odagiri T, Tashiro M. 2010. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol. J. 7:53. http://dx.doi.org/10.1186/1743-422X-7-53.
17. McKimm-Breschkin JL. 2013. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir. Viruses 7(Suppl 1):25-36. http://dx.doi.org/10.1111/irv.12047.
18. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. http://dx.doi.org/10.1001/jama.297.13.1435. (Pubitemid 46556469)
19. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402. http://dx.doi.org/10.1128/AAC.01339-05. (Pubitemid 43993177)
20. CDC. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
21. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51:983-984. http://dx.doi.org/10.1086/656439.
22. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, Li Y, Bastien N, Alexander DC, Low DE, Gubbay JB. 2011. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg. Infect. Dis. 17:1472-1474. http://dx.doi.org/10.3201/eid1708.102004.
23. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440. http://dx.doi.org/10.1128/AAC.00334-09.
24. Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM. 2012. A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011. J. Infect. Dis. 207:966-973. http://dx.doi.org/10.1093/infdis/jis776.
25. Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y. 2013. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res. 97:240-244. http://dx.doi.org/10.1016/j.antiviral.2012.12.013.
26. LeGoff J, Rousset D, Abou-Jaoudé G, Scemla A, Ribaud P, Mercier-Delarue S, Caro V, Enouf V, Simon F, Molina JM, van der Werf S. 2012. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One 7:e37095. http://dx.doi.org/10.1371/journal.pone.0037095.
27. van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van Amerongen G, Schutten M, Kuiken T, Osterhaus AD, Fouchier RA, Boucher CA, Herfst S. 2011. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 7:e1002276. http://dx.doi.org/10.1371/journal.ppat.1002276.
28. Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV. 2012. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res. 93:381-386. http://dx.doi.org/10.1016/j.antiviral.2012.01.006.
29. Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G. 2009. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the pandemic influenza virus. Antimicrob. Agents Chemother. 56:1208-1214. http://dx.doi.org/10.1128/ AAC.05994-11.
30. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31. http://dx.doi.org/10.1093/ infdis/jiq010.
31. Zhu W, Zhu Y, Qin K, Yu Z, Gao R, Yu H, Zhou J, Shu Y. 2012. Mutations in polymerase genes enhanced the virulence of 2009 pandemic H1N1 influenza virus in mice. PLoS One 7:e33383. http://dx.doi.org/10.1371/journal.pone.0033383.
32. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27:493-497.
33. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The protein data bank. Nucleic Acids Res. 28:235-242. http://dx.doi.org/10.1093/nar/28.1.235. (Pubitemid 30047768)
34. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. 2005. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26:1781-1802. http://dx.doi.org/10.1002/jcc.20289. (Pubitemid 43078511)
35. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 1983. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4:187-217. http://dx.doi.org/10.1002/jcc. 540040211.
36. Zoete V, Cuendet MA, Grosdidier A, Michielin O. 2011. SwissParam: a fast force field generation tool for small organic molecules. J. Comput. Chem. 32:2359-2368. http://dx.doi.org/10.1002/jcc.21816.
37. van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ. 2009. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog. 8:e1002914. http://dx.doi.org/10.1371/journal.ppat.1002914.
38. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. 2008. Crystal structures of oseltamivir-resistant influenzavirus neuraminidase mutants. Nature 453:1258-1261. http://dx.doi.org/10.1038/nature06956. (Pubitemid 351913590)
39. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317-6323. http://dx.doi.org/10.1016/j.vaccine.2009.07.017.
40. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. 2013. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J. Infect. Dis. 15:553-563. http://dx.doi.org/10.1093/infdis/jis726.
41. Birnkrant D, Cox E. 2009. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207. http://dx.doi.org/10.1056/NEJMp0910479.